TD Asset Management Inc Decreases Holdings in Guardant Health, Inc. (NASDAQ:GH)

TD Asset Management Inc reduced its position in Guardant Health, Inc. (NASDAQ:GHFree Report) by 51.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 138,644 shares of the company’s stock after selling 146,200 shares during the period. TD Asset Management Inc’s holdings in Guardant Health were worth $3,750,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Headlands Technologies LLC lifted its holdings in shares of Guardant Health by 362.3% in the 4th quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock valued at $64,000 after purchasing an additional 1,844 shares during the last quarter. Van ECK Associates Corp lifted its holdings in shares of Guardant Health by 29.4% in the 4th quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock valued at $73,000 after purchasing an additional 614 shares during the last quarter. AXQ Capital LP purchased a new stake in shares of Guardant Health in the 3rd quarter valued at about $202,000. Keybank National Association OH raised its stake in Guardant Health by 10.9% during the 3rd quarter. Keybank National Association OH now owns 6,933 shares of the company’s stock valued at $205,000 after acquiring an additional 680 shares during the last quarter. Finally, First Foundation Advisors purchased a new stake in Guardant Health during the 3rd quarter valued at approximately $233,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have commented on GH shares. JPMorgan Chase & Co. reduced their price objective on Guardant Health from $60.00 to $45.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. Canaccord Genuity Group upped their price objective on Guardant Health from $30.00 to $38.00 and gave the company a “buy” rating in a research note on Tuesday. Guggenheim reaffirmed a “neutral” rating on shares of Guardant Health in a research note on Friday, April 5th. Jefferies Financial Group initiated coverage on Guardant Health in a research note on Monday. They set a “buy” rating and a $32.00 price objective for the company. Finally, Piper Sandler dropped their target price on Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, February 26th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $36.91.

View Our Latest Report on Guardant Health

Insider Activity at Guardant Health

In other Guardant Health news, insider Kumud Kalia bought 2,187 shares of the stock in a transaction dated Monday, March 18th. The stock was bought at an average cost of $17.82 per share, for a total transaction of $38,972.34. Following the completion of the purchase, the insider now directly owns 12,722 shares of the company’s stock, valued at $226,706.04. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 5.50% of the stock is owned by insiders.

Guardant Health Price Performance

GH stock opened at $29.02 on Friday. Guardant Health, Inc. has a 1 year low of $15.81 and a 1 year high of $41.06. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.66 and a current ratio of 5.95. The stock’s 50 day moving average price is $21.12 and its 200 day moving average price is $22.42. The firm has a market cap of $3.55 billion, a P/E ratio of -7.40 and a beta of 1.15.

Guardant Health (NASDAQ:GHGet Free Report) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.94) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.94). The company had revenue of $168.49 million for the quarter, compared to analyst estimates of $150.51 million. Guardant Health had a negative return on equity of 246.47% and a negative net margin of 76.34%. On average, sell-side analysts expect that Guardant Health, Inc. will post -3.37 earnings per share for the current fiscal year.

Guardant Health Company Profile

(Free Report)

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Read More

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GHFree Report).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.